Skip to main content

Advertisement

SpringerLink
Log in

Acute Myeloid Leukemia: When to Transplant in First Complete Remission

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is commonly used to treat acute myeloid leukemia (AML) because it is potentially curative when other therapies have a low likelihood of success. Although most patients with newly diagnosed AML will achieve a first complete remission (CR1) with standard induction chemotherapy, obtaining a durable remission necessarily requires either further (postremission) chemotherapy or allogeneic HSCT. The decision of which of these options to choose is complex and depends on both clinical and molecular variables as well as the availability and histocompatibility of donor stem cells. Important clinical factors include the individual patient’s age, performance status, and comorbidities. Molecular and cytogenetic factors are increasingly important in stratifying patients into favorable, intermediate, and unfavorable risk categories. Whereas patients with favorable-risk cytogenetics fare better with postremission chemotherapy, allogeneic HSCT provides superior long-term survival for most non-elderly patients with intermediate-risk or unfavorable-risk AML. Because of the expanded use of umbilical cord blood as a source of hematopoietic stem cells and the use of reduced-intensity conditioning regimens, allogeneic HSCT is an option for an increasing number of patients with AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Joint Accreditation Committee, International Society for Cellular Therapy; European Group for Blood and Marrow Transplantation: EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant 2006, 37(12):1069–1085.

    Article  PubMed  CAS  Google Scholar 

  2. Mannick JA, Lochte HL, Ashley CA, et al.: Autografts of bone marrow in dogs after lethal total-body radiation. Blood 1960, 15:255–266.

    PubMed  CAS  Google Scholar 

  3. Lorenze E, Uphoff D, Reid TR, Shelton E: Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951, 12(1):197–201.

    Google Scholar 

  4. Storb R, Epstein RB, Graham TC, Thomas ED: Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970, 9(3):240–246.

    Article  PubMed  CAS  Google Scholar 

  5. Thomas ED, Buckner CD, Banaji M, et al.: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977, 49(4):511–533.

    PubMed  CAS  Google Scholar 

  6. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3(7):730–737.

    Article  PubMed  CAS  Google Scholar 

  7. Lapidot T, Sirard C, Vormoor J, et al.: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367(6464):645–648.

    Article  PubMed  CAS  Google Scholar 

  8. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5(4):275–284.

    Article  PubMed  CAS  Google Scholar 

  9. Horowitz MM, Gale RP, Sondel PM, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75(3):555–562.

    PubMed  CAS  Google Scholar 

  10. Copelan EA: Hematopoietic stem-cell transplantation. N Engl J Med 2006, 354(17):1813–1826.

    Article  PubMed  CAS  Google Scholar 

  11. Creutzig U, Ritter J, Zimmermann M: A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998, 103(1):100–109.

    Article  Google Scholar 

  12. Buchner T, Urbanitz D, Hiddemann W, et al.: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985, 3(12):1583–1589.

    PubMed  CAS  Google Scholar 

  13. Geller RB: Post-remission therapy of acute myelocytic leukemia in adults: Curability breeds controversy. Leukemia 1992, 6(9):915–925.

    PubMed  CAS  Google Scholar 

  14. Thomas ED, Buckner CD, Clift RA, et al.: Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979, 301(11):597–599.

    PubMed  CAS  Google Scholar 

  15. Tallman MS, Kopecky KJ, Amos D, et al.: Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol 1989, 7(3):326–337.

    PubMed  CAS  Google Scholar 

  16. Armand P, Kim HT, DeAngelo DJ, et al.: Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007, 13(6):655–664.

    Article  PubMed  CAS  Google Scholar 

  17. Chang C, Storer BE, Scott BL, et al.: Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007, 110(4):1379–1387.

    Article  PubMed  CAS  Google Scholar 

  18. Smith SM, Le Beau MM, Huo D, et al.: Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University Of Chicago series. Blood 2003, 102(1):43–52.

    Article  PubMed  CAS  Google Scholar 

  19. Sorror ML, Maris MB, Storb R, et al.: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106(8):2912–2919.

    Article  PubMed  CAS  Google Scholar 

  20. Sorror ML, Giralt S, Sandmaier BM, et al.: Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110(13):4606–4613.

    Article  PubMed  CAS  Google Scholar 

  21. Giles FJ, Borthakur G, Ravandi F, et al.: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007, 136(4):624–627.

    Article  PubMed  Google Scholar 

  22. Scott BL, Sandmaier BM, Storer B, et al.: Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20(1):128–135.

    Article  PubMed  CAS  Google Scholar 

  23. Bloomfield CD, Lawrence D, Byrd JC, et al.: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58(18):4173–4179.

    PubMed  CAS  Google Scholar 

  24. Byrd JC, Dodge RK, Carroll A, et al.: Patients with t(8, 21)(q22, q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999, 17(12):3767–3775.

    PubMed  CAS  Google Scholar 

  25. Ades L, Sanz MA, Chevret S, et al.: Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008, 111(3):1078–1084.

    Article  PubMed  CAS  Google Scholar 

  26. Slovak ML, Kopecky KJ, Cassileth PA, et al.: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96(13):4075–4083.

    PubMed  CAS  Google Scholar 

  27. Yanada M, Matsuo K, Emi N, Naoe T: Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a meta-analysis. Cancer 2005, 103(8):1652–1658.

    Article  PubMed  Google Scholar 

  28. • Cornelissen JJ, van Putten WL, Verdonck LF, et al.: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007, 109(9):3658–3666. This biologic randomization compares outcomes from transplantation versus chemotherapy based on availability of an HLA-identical sibling

    Article  PubMed  CAS  Google Scholar 

  29. • Koreth J, Schlenk R, Kopecky KJ, et al.: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301(22):2349–2361. This comprehensive meta-analysis of all trials to date evaluates the role of transplantation for AML in CR1.

    Article  PubMed  CAS  Google Scholar 

  30. Grimwade D, Walker H, Harrison G, et al.: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98(5):1312–1320.

    Article  PubMed  CAS  Google Scholar 

  31. Levi I, Grotto I, Yerushalmi R, et al.: Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res 2004, 28(6):605–612.

    Article  PubMed  CAS  Google Scholar 

  32. Nathan PC, Sung L, Crump M, Beyene J: Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004, 96(1):38–45.

    Article  PubMed  CAS  Google Scholar 

  33. Aoudjhane M, Labopin M, Gorin NC, et al.: Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19(12):2304–2312.

    Article  PubMed  CAS  Google Scholar 

  34. Archimbaud E, Thomas X, Michallet M, et al.: Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 1994, 12(2):262–267.

    PubMed  CAS  Google Scholar 

  35. Champlin RE, Ho WG, Gale RP, et al.: Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 1985, 102(3):285–291.

    PubMed  CAS  Google Scholar 

  36. Zittoun RA, Mandelli F, Willemze R, et al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne Dell’Adulto (GIMEMA) leukemia cooperative groups. N Engl J Med 1995, 332(4):217–223.

    Article  PubMed  CAS  Google Scholar 

  37. Burnett AK, Goldstone AH, Stevens RM, et al.: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council adult and children's leukaemia working parties. Lancet 1998, 351(9104):700–708.

    Article  PubMed  CAS  Google Scholar 

  38. Harousseau JL, Cahn JY, Pignon B, et al.: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997, 90(8):2978–2986.

    Google Scholar 

  39. Cassileth PA, Harrington DP, Appelbaum FR, et al.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339(23):1649–1656.

    Article  PubMed  CAS  Google Scholar 

  40. Suciu S, Mandelli F, de Witte T, et al.: Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003, 102(4):1232–1240.

    Article  PubMed  CAS  Google Scholar 

  41. Cornelissen JJ, Lowenberg B: Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005:151–155.

  42. Anasetti C, Perkins J, Nieder ML, Field T: Are matched unrelated donor transplants justified for AML in CR1? Best Pract Res Clin Haematol 2006, 19(2):321–328.

    Article  PubMed  Google Scholar 

  43. Moore J, Nivison-Smith I, Goh K, et al.: Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007, 13(5):601–607.

    Article  PubMed  Google Scholar 

  44. Cutler C, Li S, Ho VT, et al.: Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109(7):3108–3114.

    PubMed  CAS  Google Scholar 

  45. Yakoub-Agha I, Mesnil F, Kuentz M, et al.: Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006, 24(36):5695–56702.

    Article  PubMed  Google Scholar 

  46. Schetelig J, Bornhauser M, Schmid C, et al.: Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the Cooperative German Transplant Study Group. J Clin Oncol 2008, 26(32):5183–5191.

    Article  PubMed  Google Scholar 

  47. Lee SJ, Klein J, Haagenson M, et al.: High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110(13):4576–4583.

    Article  PubMed  CAS  Google Scholar 

  48. Krauter J, Heil G, Hoelzer D, et al.: Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 172.

  49. Tallman MS, Dewald GW, Gandham S, et al.: Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007, 110(1):409–417.

    Article  PubMed  CAS  Google Scholar 

  50. Rubinstein P, Carrier C, Scaradavou A, et al.: Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998, 339(22):1565–1577.

    Article  PubMed  CAS  Google Scholar 

  51. Rocha V, Labopin M, Sanz G, et al.: Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351(22):2276–2285.

    Article  PubMed  CAS  Google Scholar 

  52. Brunstein CG, Barker JN, Weisdorf DJ, et al.: Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110(8):3064–3070.

    Article  PubMed  CAS  Google Scholar 

  53. Hwang WY, Samuel M, Tan D, et al.: A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 2007, 13(4):444–453.

    Article  PubMed  Google Scholar 

  54. Takahashi S, Ooi J, Tomonari A, et al.: Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007, 109(3):1322–1330.

    Article  PubMed  CAS  Google Scholar 

  55. Laughlin MJ, Eapen M, Rubinstein P, et al.: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351(22):2265–2275.

    Article  PubMed  CAS  Google Scholar 

  56. Verneris MR, Brunstein CG, Barker J, et al.: Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114(19):4293–4299.

    Article  PubMed  CAS  Google Scholar 

  57. Alyea EP, Kim HT, Ho V, et al.: Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105(4):1810–1814.

    Article  PubMed  CAS  Google Scholar 

  58. Hegenbart U, Niederwieser D, Sandmaier BM, et al.: Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006, 24(3):444–453.

    Article  PubMed  CAS  Google Scholar 

  59. Appelbaum FR, Dahlberg S, Thomas ED, et al.: Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med 1984, 101(5):581–588.

    PubMed  CAS  Google Scholar 

  60. Grimwade D, Walker H, Oliver F, et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council adult and children's leukaemia working parties. Blood 1998, 92(7):2322–2333.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Brian T. Hill & Edward A. Copelan

Authors
  1. Brian T. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward A. Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian T. Hill.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hill, B.T., Copelan, E.A. Acute Myeloid Leukemia: When to Transplant in First Complete Remission. Curr Hematol Malig Rep 5, 101–108 (2010). https://doi.org/10.1007/s11899-010-0042-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-010-0042-1

Keywords

Search

Navigation